Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the Food and Drug Administration (FDA) has approved t...
Main Authors: | Luiza N. Weis, Sara M. Tolaney, Carlos H. Barrios, Romualdo Barroso-Sousa |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-09-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-021-00328-3 |
Similar Items
-
Drug Development in Tissue-Agnostic Indications
by: Pauline du Rusquec, et al.
Published: (2021-06-01) -
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
by: Valentina Tateo, et al.
Published: (2023-04-01) -
TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
by: Sun-Young Han
Published: (2021-06-01) -
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
by: Romualdo Barroso-Sousa, et al.
Published: (2023-08-01) -
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
by: Sarah Sammons, et al.
Published: (2023-08-01)